Lodestone Wealth Management LLC Invests $8.37 Million in BioNTech SE (NASDAQ:BNTX)

Lodestone Wealth Management LLC recently acquired a new stake in BioNTech SE (NASDAQ:BNTX) during the third quarter, as revealed in its latest 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 70,500 shares of BioNTech's stock, which is valued at around $8,373,000. This investment now represents 4.1% of Lodestone Wealth Management's total holdings, making BioNTech their largest investment.

Additionally, various other institutional investors have made adjustments to their shares in BioNTech. For instance, Covestor Ltd enhanced its stake by 47.2% in the first quarter, now holding 415 shares valued at $38,000 after adding 133 shares. Blue Trust Inc. significantly increased its position by an impressive 491.1% during the third quarter, owning 467 shares worth about $55,000 after acquiring an additional 388 shares. EverSource Wealth Advisors LLC added 106.3% to their holdings in the first quarter, owning 489 shares valued at $43,000 after buying an extra 252 shares. GAMMA Investing LLC also raised its stake by 86.9% in the second quarter, now owning 512 shares valued at $41,000 after adding 238 shares to their portfolio. Meanwhile, Crewe Advisors LLC invested in BioNTech for the first time with an investment of around $75,000. Currently, institutional investors collectively own 15.52% of BioNTech's stock.

BioNTech's Recent Performance

As of Friday, BioNTech shares opened at $111.48. The company has a market capitalization of approximately $26.51 billion, with a price-to-earnings ratio of -49.33 and a beta of 0.26. The stock's fifty-day moving average stands at $109.72, while its 200-day moving average is $95.77. Financial ratios indicate a quick ratio of 7.40, a current ratio of 7.54, and a low debt-to-equity ratio of 0.01. Over the last year, BioNTech's stock has fluctuated, reaching a low of $76.53 and a high of $131.49.

Recent Earnings Data

BioNTech (NASDAQ:BNTX) released its quarterly earnings report on August 5, showing a loss of ($3.36) per share, which was worse than the analysts' consensus estimate of ($2.02) by a difference of ($1.34). The company reported a negative net margin of 18.69% and a return on equity of -2.54%. Its revenue for the quarter stood at $128.70 million, which fell short of the expected $134.98 million. Compared to the previous year, these revenues marked a decline of 23.3%, with an earnings per share of ($0.86) reported last year. Analysts are forecasting a projected EPS of -2.93 for BioNTech in the current fiscal year.

Analyst Ratings

Several analysts have updated their outlooks for BioNTech stock. UBS Group increased their price target from $97.00 to $131.00 while maintaining a "neutral" rating. Similarly, JPMorgan Chase raised its recommendation from "underweight" to "neutral," with their target price updated from $91.00 to $125.00. TD Cowen upped its price target from $85.00 to $132.00 while rating it as a "hold." On the other hand, Jefferies Financial Group elevated its rating from "hold" to "buy," setting a new target of $150.00. HSBC also increased their target from $97.00 to $136.00 with a "buy" rating. In total, five research analysts have given the stock a "hold" rating, eight a "buy" rating, and one a "strong buy" rating. The general consensus is a "Moderate Buy" with an average price target set at $135.54.

About BioNTech SE

BioNTech SE is a biotechnology company focused on developing and commercializing immunotherapies to combat cancer and other infectious diseases. The company is advancing several product candidates in its FixVac pipeline, including BNT111 for advanced melanoma (currently in Phase II), BNT112 for prostate cancer (in Phase I/IIa), BNT113 for HPV 16+ head and neck cancers (in Phase II), as well as others targeting triple-negative breast cancer, ovarian cancer, and non-small cell lung cancer.

investment, finance, healthcare